Show simple item record

dc.contributor.authorFennell, Dean
dc.contributor.authorDulloo, Sean
dc.date.accessioned2022-03-09T15:13:00Z
dc.date.available2022-03-09T15:13:00Z
dc.date.issued2022
dc.identifier.citationFennell, D. A., & Dulloo, S. (2022). Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(1), 34–37. https://doi.org/10.1016/j.jtho.2021.08.004en_US
dc.identifier.other10.1016/j.jtho.2021.08.004
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15224
dc.description.abstractNo abstract available.
dc.description.urihttps://www.jto.org/article/S1556-0864(21)02395-9/fulltexten_US
dc.language.isoenen_US
dc.subjectantineoplastic combined chemotherapy protocolsen_US
dc.subjectbevacizumaben_US
dc.subjectmesotheliomaen_US
dc.subjectlung neoplasmsen_US
dc.titleChemotherapy with or without bevacizumab should be the standard of care for first-line unresectable epithelioid mesotheliomaen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.jtho.2021.08.004en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2022
html.description.abstractNo abstract available.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record